POT-4

POT-4, a complement component C3 inhibitor formulated to be dosed less frequently than currently approved AMD therapies. There are strongly linked variants of genes encoding components of the complement system with a predisposition toward AMD. POT-4 binds tightly to complement component C3, preventing its participation in the complement activation cascade. As C3 is the central component of all major complement activation pathways, its inhibition effectively shuts down downstream complement activation that could otherwise lead to local inflammation, tissue damage and upregulation of angiogenic factors such as vascular endothelial growth factors (VEGF). POT-4 prevent overactivation of the complement pathway.